Sign in
Taking people in HungaryPhase 1/2

Tests APG-2575 in adults with relapsed or hard-to-treat chronic lymphocytic leukemia

Tests the pill APG-2575, alone or with other drugs, in adults with leukemia.

Key facts

Who runs it
Ascentage Pharma Group Inc.
Where
Debrecen, Kaposvár, and Nyíregyháza, HungarySee the 3 sitesAlso in 1 other country, 2 sites
Registry title
A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Status
Recruiting
Phase
Phase 1/2
People taking part
60 people, planned
Started
20 Dec 2021
Expected to end
3 Nov 2028
Type of study
Interventional
Record updated
18 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or did not respond to earlier treatment. In some groups, people who have not been treated before can also join.

Age
18 years or older
Sex
All sexes can join
Disease stage
CLL/SLL confirmed by tissue tests, needing treatment, with documented signs that the disease is getting worse. Blood counts, kidney and liver function must be adequate. ECOG score of 2 or lower.
Earlier treatment
At least one earlier treatment for CLL/SLL that did not work or stopped working. In some groups, people with no earlier treatment or whose disease did not respond to venetoclax can also join. Earlier anti-Bcl-2 treatment is generally not allowed.

Main reasons for not taking part

  • Active Richter's syndrome or known central nervous system involvement
  • Active infection with HIV, hepatitis B, hepatitis C or COVID-19
  • Pregnant or breastfeeding
  • Heart problems such as New York Heart Association class 2 or higher, or a heart attack or unstable angina within 3 months
  • Allogeneic stem cell transplant less than 90 days ago, CAR-T therapy less than 30 days ago, or active graft-versus-host disease

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • ≥18 years of age
  • Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures)
  • Willingness and ability to comply with study procedures and follow-up examination
  • Histologically confirmed chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL) according to the 2018 international workshop (IW) CLL criteria who must have relapsed or be refractory to at least one prior therapy for CLL/SLL and require treatment by 2018 IWCLL criteria. In addition, for APG-2575, 600 plus acalabrutinib combination may be (1) treatment naïve or (2) refractory to venetoclax. Patients in APG-2575 plus ibrutinib Cohort C and in APG-2575 plus zanubrutinib Cohort D may be relapsed/refractory or treatment naïve
  • Eastern Cooperative Oncology Group (ECOG) score ≤ 2
  • Patients must have objectively documented evidence of disease progression prior to study entry such as: escalating lymphocytes count with an increase > 50% over a period of two months or doubling time in less than 6 months; enlarging adenopathy or splenomegaly; increasing cytopenias; clinical B symptoms night sweats, fatigue, > 10 % weight loss in 6 months, fevers > 100.50 F or 38.00 C for ≥ one month without infection
  • Adequate bone marrow function independent of growth factor: • Absolute neutrophil count (ANC)≥ 1.0× 109/L. • Platelet count ≥ 50 x 109/L (entry platelet count must be independent of transfusion within 7 days of first dose of study drug). • Hemoglobin ≥ 8.0 g/dL independent of transfusion within 7 days of first dose of study drug
  • Adequate renal and hepatic function as indicated by: a. Creatinine clearance must be ≥ 50 mL/min, calculated using the Cockcroft and Gault formula(140-Age) x mas (kg)/ (72x creatinine mg/dL); multiply by 0.85 if female (Cockcroft 1976) or measured by 24-hour urine collection. b. Total bilirubin ≤1.5 x ULN, except patient with known Gilbert’s syndrome or resolving hemolytic anemia. c. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) <3 x ULN. Alkaline phosphatase < 3×ULN
  • Females of childbearing potential (i.e. not postmenopausal for at least 2 years or surgically sterile) must have negative results for pregnancy test performed: a. At screening on a serum sample obtained within 14 days prior to the first study drug administration. b. Prior to dosing on a urine sample obtained on the first day of study drug administration, if it has been>7 days since obtaining the serum pregnancy test results
  • Females of childbearing potential and non-sterile males must practice at least one of the following methods of birth control with partner(s) throughout the study and for 90 days after discontinuing study drug: a. Total abstinence from sexual intercourse as the preferred lifestyle of the patient; periodic abstinence is not acceptable; b. Surgically sterile partner(s); acceptable sterility surgeries are vasectomy, bilateral tubal ligation, bilateral oophorectomy or hysterectomy; c. Intrauterine device (IUD); d. Double-barrier method (contraceptive sponge, diaphragm or cervical cap with spermicidal jellies or cream AND a condom); e. Hormonal contraceptives (oral, parenteral, vaginal ring or transdermal) for at least 3 months prior to study drug administration. If hormonal contraceptives are used, the specific contraceptive must have been used for at least 3 months prior to study drug administration
  • Male patients must refrain from sperm donation, from initial study drug administration until 90 days after the last dose of study drug

Who cannot take part

  • Patient has undergone allogeneic stem cell transplant < 90 days
  • Concurrent treatment with an investigational agent, received biologics (≤14 days), or small molecule targeted therapies (≤5 half-life) or other anti-cancer therapies (including chemotherapy) ≤14 days of first dose of study drug
  • Has received the following within 7 days prior to the first dose of study drug: a. Steroid therapy at a dose greater than prednisone 20 mg daily (or equivalent) for antineoplastic intent; b. CYP3A inhibitors such as fluconazole, ketoconazole, and clarithromycin; c. Potent CYP3A inducers such as rifampin, carbamazepine, phenytoin, and St. John’s wort
  • Radiation within 14 days of study entry
  • Continuance of toxicities due to prior radiotherapy or chemotherapy agents that have not recovered to ≤ grade 1 or baseline, except alopecia or neuropathy
  • Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients with active wound healing, patients who have had major surgery within 28 days from 1st dose of study drug
  • Uncontrolled concurrent illness including, but not limited to: uncontrolled diabetes mellitus, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements
  • Patient has undergone CAR-T therapy < 30 days
  • Active Richter’s Syndrome (patients with previously treated Richter’s Syndrome will be permitted if they are in remission)
  • Prior anti-Bcl-2 treatment (except patients who discontinued treatment for reasons other than disease progression and patients in the APG-2575 plus BTKi cohorts)
  • For the BTKi and APG-2575 combination cohorts: (1) Patients who discontinued due to a specific BTKi toxicity may not be retreated with that BTKi (Note: Patients who received a BTKi therapy may participate whether or not they progressed following BTKi treatment). (2) Patients in the cohort receiving acalabrutinib with the capsule formulation and not tablet formulation, who require concomitant treatment with a proton pump inhibitor (e.g., omeprazole esomeprazole, lansoprazole, etc.) at study entry. (Patients receiving proton pump inhibitors who switch to H2 receptor antagonists or antacids are eligible for enrollment into this study arm.) (3) Requires or is receiving anticoagulation therapy with warfarin or equivalent vitamin K antagonists within 7 days of first dose of the study drug(s)
  • Active hepatitis B infection, as defined seropositivity for Hep B surface antigen (HBsAg) or known active Hepatitis C infection as determined by Hepatitis C antibody with elevated liver enzymes as defined in the inclusion criteria or any other evidence of active Hepatitis C such as currently on treatment; or active COVID-19 infection. (Patients who have received COVID-19 vaccination will be considered as eligible for the study)
  • Prior malignancy that requires treatment, with exception of hormonal therapy and any cancer with recurrence within 2 years of screening (except for non-melanoma skin cancer or adequately treated carcinoma in situ of cervix or breast). Cancer treated within 2 years with curative intent and without recurrence as well as prostate cancer on active surveillance are allowed
  • Has a cardiovascular disability status of New York Heart Association Class ≥ 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea or anginal pain
  • Unstable angina or myocardial infarction within 3 months of enrollment
  • Patient has active graft-versus-host disease or requires immunosuppressive therapy
  • Unable to swallow capsules or have gastrointestinal conditions that could affect the absorption of APG-2575 in the opinion of the investigator
  • Any other condition or circumstance that would, in the opinion of the investigator, make the patient unsuitable for participation in the study
  • Active pathogen infections including human immunodeficiency virus syndrome (HIV) infection
  • Patient is pregnant or breastfeeding
  • QTcF interval> 480ms (Bazetts or Fredericia) or other remarkable abnormality of ECG, including second-degree type II atrioventricular block, third-degree atrioventricular block or bradycardia (ventricular rate consistently less than 50 beats per minute)
  • Has known central nervous system (CNS) involvement

Where in Hungary

Also in 1 other country, 2 sites

  • University of DebrecenDebrecen, HungaryTaking people
  • Somogy Vármegyei Kaposi Mór Oktató KórházKaposvár, HungaryTaking people
  • Szabolcs Szatmár Bereg Vármegyei OktatókórházNyíregyháza, HungaryTaking people

About the trial

What the trial wants to find out

Phase Ib To assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of APG-2575, administered orally as monotherapy or in combination with rituximab or acalabrutinib in patients with relapsed and/or refractory CLL/SLL. Phase II To assess the safety and efficacy of APG-2575 alone or in combination with other therapeutic agents such as rituximab, acalabrutinib, ibrutinib or zanubrutinib in patients with relapsed and/or refractory or treatment naïve CLL/SLL. (Efficacy assessment parameters will include: ORR, CR, PR, PR-L, DOR, PFS, OS, MRD by 8-color flow cytometry with a minimum sensitivity of 10-4 (0.01%) in peripheral blood and bone marrow, time to CR and/or MRD negativity.)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (SACRED).
Plain-language title
Tests APG-2575 in adults with relapsed or hard-to-treat chronic lymphocytic leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
18 August 2026